440 related articles for article (PubMed ID: 19650755)
1. Impact of treatment efficacy and dosing frequency on cost-effectiveness of bisphosphonate treatment for osteoporosis: a perspective.
Boonen S
Curr Med Res Opin; 2009 Oct; 25(10):2335-41. PubMed ID: 19650755
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of bisphosphonate therapies for women with postmenopausal osteoporosis: implications of improved persistence with less frequently administered oral bisphosphonates.
Earnshaw SR; Graham CN; Ettinger B; Amonkar MM; Lynch NO; Middelhoven H
Curr Med Res Opin; 2007 Oct; 23(10):2517-29. PubMed ID: 17825128
[TBL] [Abstract][Full Text] [Related]
3. Improving compliance and persistence with bisphosphonate therapy for osteoporosis.
Emkey RD; Ettinger M
Am J Med; 2006 Apr; 119(4 Suppl 1):S18-24. PubMed ID: 16563937
[TBL] [Abstract][Full Text] [Related]
4. Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates.
Cole RE
Postgrad Med; 2011 Mar; 123(2):131-44. PubMed ID: 21474901
[TBL] [Abstract][Full Text] [Related]
5. Potential clinical and economic impact of nonadherence with osteoporosis medications.
Hiligsmann M; Rabenda V; Gathon HJ; Ethgen O; Reginster JY
Calcif Tissue Int; 2010 Mar; 86(3):202-10. PubMed ID: 20205345
[TBL] [Abstract][Full Text] [Related]
6. Osteoporosis management: translating research into optimal fracture protection II.
Singer AJ; Boonen S
Curr Med Res Opin; 2008 Jun; 24(6):1789-96. PubMed ID: 18559165
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonate therapy for osteoporosis: combining optimal fracture risk reduction with patient preference.
Beard MK
Curr Med Res Opin; 2012 Jan; 28(1):141-7. PubMed ID: 22103779
[TBL] [Abstract][Full Text] [Related]
8. The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates.
McHorney CA; Schousboe JT; Cline RR; Weiss TW
Curr Med Res Opin; 2007 Dec; 23(12):3137-52. PubMed ID: 17988435
[TBL] [Abstract][Full Text] [Related]
9. The cost-effectiveness of an RCT to establish whether 5 or 10 years of bisphosphonate treatment is the better duration for women with a prior fracture.
Stevenson MD; Oakley JE; Lloyd Jones M; Brennan A; Compston JE; McCloskey EV; Selby PL
Med Decis Making; 2009; 29(6):678-89. PubMed ID: 19509121
[TBL] [Abstract][Full Text] [Related]
10. A review of the cost effectiveness of bisphosphonates in the treatment of post-menopausal osteoporosis in Switzerland.
Lippuner K; Pollock RF; Smith-Palmer J; Meury T; Valentine WJ
Appl Health Econ Health Policy; 2011 Nov; 9(6):403-17. PubMed ID: 21910511
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of pharmacological agents in managing osteoporosis in the old old: review of the evidence.
Inderjeeth CA; Foo AC; Lai MM; Glendenning P
Bone; 2009 May; 44(5):744-51. PubMed ID: 19130909
[TBL] [Abstract][Full Text] [Related]
12. A Markov model simulation of the impact of treatment persistence in postmenopausal osteoporosis.
Cotté FE; Fautrel B; De Pouvourville G
Med Decis Making; 2009; 29(1):125-39. PubMed ID: 18566486
[TBL] [Abstract][Full Text] [Related]
13. An integrated approach: bisphosphonate management for the treatment of osteoporosis.
Owens G; Jackson R; Lewiecki EM
Am J Manag Care; 2007 Dec; 13 Suppl 11():S290-308; quiz S309-12. PubMed ID: 18095779
[TBL] [Abstract][Full Text] [Related]
14. Is treatment of early postmenopausal women with bisphosphonates justified?
Epstein S
Int J Clin Pract; 2007 Jun; 61(6):963-71. PubMed ID: 17504359
[TBL] [Abstract][Full Text] [Related]
15. Drug insight: the use of bisphosphonates for the prevention and treatment of osteoporosis in men.
Brown SA; Guise TA
Nat Clin Pract Urol; 2007 Jun; 4(6):310-20. PubMed ID: 17551535
[TBL] [Abstract][Full Text] [Related]
16. How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy.
Gold DT; Alexander IM; Ettinger MP
Ann Pharmacother; 2006 Jun; 40(6):1143-50. PubMed ID: 16735667
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of hormone therapy in women at high risks of fracture in Sweden, the US and the UK--results based on the Women's Health Initiative randomised controlled trial.
Lekander I; Borgström F; Ström O; Zethraeus N; Kanis JA
Bone; 2008 Feb; 42(2):294-306. PubMed ID: 18053789
[TBL] [Abstract][Full Text] [Related]
18. Clinical and therapeutic aspects of osteoporosis.
Compston J
Eur J Radiol; 2009 Sep; 71(3):388-91. PubMed ID: 19660883
[TBL] [Abstract][Full Text] [Related]
19. [How to prevent early postmenopausal fracture risk? Proposition of a strategy].
Trémollieres F; Pouilles JM; Ribot C
Gynecol Obstet Fertil; 2009 Jan; 37(1):50-6. PubMed ID: 19110461
[TBL] [Abstract][Full Text] [Related]
20. [New development in bisphosphonate treatment. Clinical significance of combinatorial therapies with bisphosphonates and parathyroid hormone for osteoporosis].
Takeuchi Y
Clin Calcium; 2009 Jan; 19(1):85-90. PubMed ID: 19122268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
